866-997-4948(US-Canada Toll Free)

Vectibix (Gastric Cancer) - Analysis and Forecasts to 2020

Published By :

GlobalData

Published Date : Oct 2011

Category :

Cancer

No. of Pages : 25 Pages


GlobalDatas pharmaceuticals report, Vectibix (Gastric Cancer) - Analysis and Forecasts to 2020 provides Vectibix sales forecasts for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2014-2020). The report also includes information on Parkinson's Disease market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Scope

  • Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
  • Analysis and review of Vectibix including sales data
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of Vectibix including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Detailed sales forecast for 2014-2020 for Vectibix in the US and EU5 and Japan

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drugs performance 
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets
Table of Contents

1 Table of contents 2
1.1 List of Tables 2
1.2 List of Figures 3

2 Introduction 4
2.1 Gastric Cancer Market 4
2.2 Gastric Cancer Disease 4
2.3 GlobalData Market Forecasts Report Guidance 6

3 Gastric Cancer Disease Market: Market Characterization 7
3.1 Gastric Cancer Disease Market 7
3.2 Gastric Cancer Disease Market Forecast and CAGR 7
3.3 Drivers for the Gastric Cancer Disease Market 8
3.3.1 High Incidence 8
3.3.2 High Prevalence 9
3.3.3 Low Initial Diagnosis Rate 9
3.3.4 High Mortality Rate 9

4 Tumor Node Metastases (TNM) Classification of Gastric Cancer 10

5 Vectibix 13

5.1 Introduction 13
5.2 Mechanism of Action 13
5.3 Clinical Studies 13
5.4 Factors affecting Sales 13
5.4.1 Gastric Cancer Market 13
5.4.2 Cost of Vectibix 13
5.4.3 Absence of competition in the first line treatment of inoperable locally advanced gastric cancer 14
5.4.4 Absence in first line of treatment of operable metastatic gastric cancer 14
5.5 Drug Risk Benefit Score 14
5.5.1 Efficacy 14
5.5.2 Safety 15
5.5.3 Compliance 15
5.5.4 Dosing Convenience 15
5.6 Intensity of Competition 15
5.7 Sales forecast 16
5.7.1 Target patient Pool of Vectibix 16
5.7.2 Dosing 17
5.7.3 Market Penetration 17
5.7.4 Annual Cost of Therapy 18
5.7.5 Sales Projection of Vectibix 18

6 Gastric Cancer Market: Appendix 23
6.1 Market Definitions 23
6.2 List of Abberiviations 23
6.3 Research Methodology 23
6.3.1 Coverage 23
6.3.2 Secondary Research 23
6.3.3 Forecasting 24
6.3.4 Number of Patients Approved to take the Drug 24
6.3.5 Net Penetration of Drug 24
6.3.6 Net Annual Dosing 24
6.3.7 Annual Cost of Therapy 25
6.3.8 Primary Research 25
6.3.9 Expert Panels 25
6.4 Contact Us 25
6.5 Disclaimer 25
6.6 Sources 25

List of Table


Table 1: Gastric Cancer Incidence and Mortality,20082030 5
Table 2: Gastric Cancer, Estimated Global Market ($bn),20092020 7
Table 3: Drug Risk Benefit Score of Vectibix 14
Table 4: Annual Cost of Therapy of Vectibix 18
Table 5: Gastric Cancer,The US,EU-5 and Japan, Estimated Sales of Vectibix($m),20142020 19
Table 6: Gastric Cancer,The US, Estimated Sales of Vectibix($m),20142020 20
Table 7: Gastric Cancer,EU-5, Estimated Sales of Vectibix($m),20142020 21
Table 8: Gastric Cancer,Japan, Estimated Sales of Vectibix($m),20142020 22

List of Chart


Figure 1: Percentage Distribution of the Top 20 Cancers 4
Figure 2: Fatality =[(%Distribution of Incidence)-(%Distribution of Mortality)] of the Top 20 Cancers 5
Figure 3: Per Capita Cigarette Consumption Curve, the US,1976-2006 6
Figure 4: Estimated Global Gastric Cancer Market,20092020 7
Figure 5: Oncology,Global,Incidence(in million),20082030 8
Figure 6: Gastric Cancer, Global, Incidence(in million),20082030 8
Figure 7: Broad Classification of Gastric Cancer in the US and EU 10
Figure 8: Broad Classification of Gastric Cancer in Japan 10
Figure 9: Detailed TNM Classification 11
Figure 10: Classification of Gastric Cancer in the US and EU-5 12
Figure 11: Classification of Gastric Cancer in Japan 12
Figure 12: Drug Model Diagram of Vectibix in the US and EU 16
Figure 13: Drug Model Diagram of Vectibix in Japan 17
Figure 14: Gastric Cancer,The US,EU-5 and Japan,Estimated Sales of Vectibix ($m),20142020 19
Figure 15: Gastric Cancer, The US, Estimated Sales of Vectibix($m),2014-2020 20
Figure 16: Gastric Cancer, EU-5, Estimated Sales of Vectibix($m),2014-2020 21
Figure 17: Gastric Cancer, Japan, Estimated Sales Forecast of Vectibix($m),2014-2020 22

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *